Scandinavian Tobacco Group A/S: Initiation of new share buy-back programme of up to DKK 850 million
|Company Announcement |
Copenhagen, 10 November 2023
Initiation of new share buy-back programme of up to DKK 850 million.
The Board of Directors of Scandinavian Tobacco Group A/S has decided to initiate a new share buy-back programme of up to DKK 850 million.
The purpose of the share buy-back programme is to adjust the Group’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The Board of Directors intends to propose no later than to the annual general meeting in 2025 that the shares acquired under the programme, that are not needed to meet the Group's obligations under the incentive programme, be cancelled.
The share buy-back programme will run from 13 November 2023 to 28 February 2025 at the latest. The Company may terminate the programme at any time. Scandinavian Tobacco Group will buy its own shares up to an aggregated price of DKK 850 million. Part of the programme will be conducted in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules.
The programme is initiated based on the Company’s articles of association which currently authorise the Company to acquire up to 10% of the Company´s total share capital, i.e. currently up to nominally DKK 8.7 million own shares. Prior to the share buy-back, Scandinavian Tobacco Group holds a total of 381,749 own shares, corresponding to 0.44% of the current total share capital.
Scandinavian Tobacco Group has appointed Nordea Danmark, Filial af Nordea Bank Abp, Finland (“Nordea”) as lead manager for the share buy-back programme. Nordea will make its own trading decisions independently of and without influence from Scandinavian Tobacco Group and execute the buy-back within the announced limits.
No shares may be bought at a price exceeding the higher of (i) the price of the last independent trade and (ii) the highest current independent purchase bid on the trading venue where the purchase is carried out.
The maximum number of shares that may be purchased on each business day may not exceed 25% of the average daily trading volume over the last 20 trading days prior to the date of purchase on the trading venue where the purchase is carried out.
Chr. Augustinus Fabrikker Aktieselskab has informed Scandinavian Tobacco Group that it intends to maintain a long-term ownership share in the Company of between 25.0% and 30.0% and, therefore wishes to sell shares to the Company under the share buy-back programme. Consequently, Chr. Augustinus Fabrikker Aktieselskab has informed Scandinavian Tobacco Group that it will participate in the share buy-back programme on a pro-rata basis reflecting its current holding of 27.30% of the outstanding share capital.
C.W. Obel A/S has informed Scandinavian Tobacco Group that it intends to maintain a long-term ownership share in the Company of between 10.0% and 15.0% and, therefore wishes to sell shares to the Company under the share buy-back programme. Consequently, C.W. Obel A/S has informed Scandinavian Tobacco Group that it will participate in the share buy-back programme on a pro-rata basis reflecting its current holding at 12.59% of the outstanding share capital.
Accordingly, it has been agreed between Scandinavian Tobacco Group and Chr. Augustinus Fabrikker Aktieselskab and C.W. Obel A/S, respectively, that on a weekly basis each such shareholder will sell and transfer such number of shares to Scandinavian Tobacco Group that corresponds to each such shareholder’s notional ownership share of the shares purchased by Scandinavian Tobacco Group in the share buy-back programme during the said week. The price for the shares will be equal (on a per share basis) to the volume-weighted average purchase price for all the shares purchased in the market under the share buy-back programme during the relevant weekly trading period.
In case the purchase price per share calculated in accordance with the foregoing would be higher than 105% or lower than 90% of the closing price of the share quoted on Nasdaq Copenhagen A/S at the end of the relevant weekly trading period, no shares will be transferred from Chr. Augustinus Fabrikker Aktieselskab or C.W. Obel A/S for that weekly trading period.
Nordea Danmark, Filial af Nordea Bank Abp, Finland ("Nordea") acts as lead manager for the share buy-back programme related to Chr. Augustinus Fabrikker Aktieselskab and C.W. Obel A/S.
Scandinavian Tobacco Group will report on trade activity under the share buy-back programme in weekly company announcements.
For further information, please contact:
Torben Sand, Head of IR & Communication, phone +45 5084 7222 or email@example.com
Eliza Dabbagh, IR and Communication, phone +45 5080 7619 or firstname.lastname@example.org
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Biotalys Provides Company Update29.11.2023 07:00:00 CET | Press release
Review by new CEO Kevin Helash leads to focus on core capabilities and organizational changes Ghent, BELGIUM , Nov. 29, 2023 (GLOBE NEWSWIRE) -- Press release – Regulated information – Inside information (*) Progress to next-generation AGROBODY™ technology platform Update on product pipeline and regulatory review for EVOCA™(**)CSO Dr. Carlo Boutton to drive all research and early development while Dr. Eva Van Hende to head regulatory and field development; COO Luc Maertens and CBO Patrick McDonnell leaving the company Management to host a conference call and live webcast today at 15:00 CET / 14:00 GMT / 09:00 AM EST, details below Biotalys (Euronext – BTLS), today provided a company update following a strategic review of the company by CEO Kevin Helash and the board of directors. The review leads to a shift to the second-generation AGROBODY™ technology to develop protein-based biocontrols for crop and food protection. This move to AGROBODY 2.0 entails organizational changes to concentr
Nasdaq Launches New Technology to Scale Global Carbon Markets29.11.2023 07:00:00 CET | Press release
Technology Securely Digitizes the Issuance, Settlement, and Custody of Carbon Credits Service Uses Smart Contract Language, Deployed via Private Centralized Database or Private, Blockchain Technology for Enterprises Puro.earth to Register Carbon Removal Credits Using the Technology NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the launch of a pioneering new technology that securely digitizes the issuance, settlement, and custody of carbon credits. It will be provided to market infrastructures, registry platforms, and other service providers globally. The service will ultimately support the development and institutionalization of global carbon markets. Despite being a relatively young market the carbon credit operating model is characterized by bilateral trading and a heavy reliance on manual interaction, providing limited ability to scale as the market develops. This inflexibility has also led to an absence of standardization – where credit data can
Hydros kapitalmarkedsdag 2023: En pioner i det grønne aluminiumskiftet med kraft fra fornybar energi29.11.2023 07:00:00 CET | Pressemelding
Hydro øker satsingen på å utnytte mulighetene som oppstår gjennom økt etterspørsel etter lavkarbonaluminium. Fram mot 2030 vil Hydro øke veksten i resirkulering av aluminium og ekstruderte produkter, og styrke ambisjonene innen produksjon av fornybar energi. Hydro vil gjennomføre planlagt avkarbonisering og bidra til en omstilling som er rettferdig og naturpositiv, samtidig som markedet for grønnere aluminium videreutvikles. Dette er hovedtemaene på Hydros kapitalmarkedsdag 2023. Hovedpunkter Forventer en økning på opptil 2 milliarder kroner i grønnere inntjening innen 2030Trapper opp veksten i Extrusions til en EBITDA på 10-12 milliarder kroner i 2030Trapper opp veksten i resirkulering til en EBITDA på 5-8 milliarder kroner i 2030, delvis gjennom å øke mengden brukt aluminiumskrap til 850.000-1.200.000 tonn innen 2030Øker målet for utslippskutt for CO2 fram mot 2030, der målet om 30 prosent reduksjon opprettholdes til tross for porteføljeendringer, og trapper opp naturpositive tiltak
Hydro Capital Markets Day 2023: Pioneering the green aluminium transition, powered by renewable energy29.11.2023 07:00:00 CET | Press release
Hydro is shifting gear to capture opportunities created by increased demand for low-carbon aluminium. Towards 2030, Hydro will step up growth in aluminium recycling and extrusions, and in its ambitions within renewable power generation. Hydro will execute on its decarbonization roadmap, and contribute to nature positive and a just transition, while shaping the market for greener aluminium. These are key topics for Hydro’s Capital Markets Day 2023. Key highlights Expecting up to NOK 2 billion greener earnings uplift by 2030Stepping up growth in Extrusions to NOK 10-12 billion EBITDA in 2030Stepping up growth in Recycling to NOK 5-8 billion EBITDA in 2030, partially driven by increasing post-consumer scrap to 850-1,200 kt by 2030Increasing CO2 reduction target until 2030, maintaining 30% target despite portfolio changes, and stepping up nature positive efforts through initiatives on biodiversity, waste handling and land useIncreasing improvement program to NOK 14 billion in 2030, includi
Sequana Medical announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure29.11.2023 07:00:00 CET | Press release
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 29 November 2023, 07:00 am CET Data from all three patients in non-randomized cohort treated with DSR 2.0 indicate safe and effective maintenance of euvolemia without the need for loop diuretics,considerable benefit in cardiorenal status and dramatic improvement in diuretic response and loop diuretic requirements up to 11 weeks post DSR treatment DSMBi review planned for early Q1 2024 to approve start of randomized controlled cohort of up to 30 US patients Ghent, Belgium – 29 November 2023– Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "SequanaMedical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all three patients from the non-randomized cohort of the MOJAVE study were successfully treated with DSR 2.0. Data from the third patient show similar beneficial effects of DSR therapy as reported previously in the first two patientsii. Dr. Oliver Gödje,